Skip to main
PCSA
PCSA logo

Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target

Processa Pharmaceuticals (PCSA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Processa Pharmaceuticals Inc. has demonstrated a narrowing of its estimated net loss per share for full-year 2026 to $0.15, down from a prior estimate of $0.20, indicating improved financial efficiency despite an increased share count. The company is positioned for potential value enhancement due to promising interim data from the mid-stage trial of its lead product, NGC-Cap, which could serve as a significant inflection point for the stock. Furthermore, the recent securing of a strategic investment and the exploration of cryptocurrency treasury strategies highlight Processa's proactive approach to growth and financial stability, contributing to a favorable financial outlook.

Bears say

Processa Pharmaceuticals is projected to incur a full-year net loss of $0.43 per share in 2025, indicating ongoing financial challenges and insufficient profitability in the near future. The company faces risks associated with regulatory approvals, increased competition affecting pricing and market penetration, as well as potential issues relating to partnerships. Additionally, there exists a concern regarding possible dilution risk in the near to medium term, which could further impact the stock's attractiveness to investors.

Processa Pharmaceuticals (PCSA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Processa Pharmaceuticals (PCSA) Forecast

Analysts have given Processa Pharmaceuticals (PCSA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Processa Pharmaceuticals (PCSA) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Processa Pharmaceuticals (PCSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.